INNOVIVA, INC. Inventory, Raw Materials, Net of Reserves
INNOVIVA, INC. (INVA) had Inventory, Raw Materials, Net of Reserves of $18.72 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Notes › Inventory, Net, Items Net of Reserve Alternative
us-gaap:InventoryRawMaterialsNetOfReserves · last filed 2026-08-05
- 2026-06-30: Inventory, Raw Materials, Net of Reserves $18.72M.
- 2026-03-31: Inventory, Raw Materials, Net of Reserves $17.46M.
- 2025-12-31: Inventory, Raw Materials, Net of Reserves $16.33M.
- 2025-09-30: Inventory, Raw Materials, Net of Reserves $14.37M.
| Period end | Inventory, Raw Materials, Net of Reserves |
|---|---|
| 2026-06-30 | $18.72M 10-Q · filed 2026-08-05 |
| 2026-03-31 | $17.46M 10-Q · filed 2026-05-06 |
| 2025-12-31 | $16.33M 10-Q · filed 2026-08-05 |
| 2025-09-30 | $14.37M 10-Q · filed 2025-11-05 |
| 2025-06-30 | $10.55M 10-Q · filed 2025-08-06 |
| 2025-03-31 | $10.62M 10-Q · filed 2025-05-07 |
| 2024-12-31 | $11.11M 10-K · filed 2026-02-25 |
| 2024-09-30 | $9.53M 10-Q · filed 2024-11-06 |
| 2024-06-30 | $9.53M 10-Q · filed 2024-07-31 |
| 2024-03-31 | $9.53M 10-Q · filed 2024-05-08 |
| 2023-12-31 | $11.26M 10-K · filed 2025-02-26 |
| 2023-09-30 | $8.86M 10-Q · filed 2023-11-01 |
| 2023-06-30 | $8.86M 10-Q · filed 2023-08-02 |
| 2023-03-31 | $5.76M 10-Q · filed 2023-05-09 |
| 2022-12-31 | $5.76M 10-K/A · filed 2024-03-05 |
| 2022-09-30 | $5.76M 10-Q · filed 2022-11-09 |
| 2014-06-30 | $0.00 10-Q · filed 2014-08-07 |
| 2014-03-31 | $4.00M 10-Q · filed 2014-05-07 |
| 2013-12-31 | $5.14M 10-K · filed 2015-02-27 |
| 2013-09-30 | $4.08M 10-Q · filed 2013-11-01 |
| 2013-06-30 | $3.53M 10-Q · filed 2013-08-01 |
| 2013-03-31 | $3.53M 10-Q · filed 2013-05-01 |
| 2012-12-31 | $5.67M 10-K · filed 2014-03-03 |
| 2012-06-30 | $4.30M 10-Q · filed 2012-08-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |